Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Innovent Biologics Inc

1801:HKG.HZ

Innovent Biologics Inc

Actions
  • Price (HKD)39.15
  • Today's Change0.600 / 1.56%
  • Shares traded7.29m
  • 1 Year change+4.54%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Innovent Biologics Inc grew revenues 36.21% from 4.56bn to 6.21bn while net income improved from a loss of 2.18bn to a smaller loss of 1.03bn.
Gross margin81.69%
Net profit margin-16.56%
Operating margin-16.85%
Return on assets-5.38%
Return on equity-8.84%
Return on investment-6.80%
More ▼

Cash flow in CNYView more

In 2022, cash reserves at Innovent Biologics Inc fell by 343.24m. Cash Flow from Financing totalled 2.89bn or 63.47% of revenues. In addition the company used 1.92bn for operations while cash used for investing totalled 1.44bn.
Cash flow per share0.0336
Price/Cash flow per share1,180.93
Book value per share8.35
Tangible book value per share7.51
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.